- Home
- SST vs MRKR Comparison
SST vs MRKR Comparison
Compare SST & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | MRKR |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 23.0M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SST | MRKR |
|---|---|---|
| Price | $1.77 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $11.25 |
| AVG Volume (30 Days) | 19.3K | ★ 115.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $0.81 |
| 52 Week High | $11.30 | $4.07 |
Technical Indicators
Market Signals| Indicator | SST | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 16.84 | 43.13 |
| Support Level | $0.34 | $1.36 |
| Resistance Level | $4.61 | $1.44 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 5.88 | 14.32 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.